Description

Resiniferatoxin ((+)-Resiniferatoxin), is a selective agonist of transient receptor potential vanilloid 1 (TRPV1) receptor agonist. Resiniferatoxin can be isolated from the Euphorbia resinifera plant. Resiniferatoxin eliminates TRPV1+ primary sensory afferents and blunt cardiac sympathetic afferent reflex for a relatively long period.

In Vitro

Resiniferatoxin causes extremely prolonged channel opening and calcium influx, which results in cytotoxicity to the TRPV1-positive pain fibers or cell bodies[1].

Biofargo has not independently confirmed the accuracy of these methods. They are for reference only.
Resiniferatoxin Related Antibodies

TRPM8 Antibody

TRPM7 Antibody

TrpC1 Antibody

In Vivo

Resiniferatoxin (2 μg/10 μl; injected intrathecally into the T2/T3 interspace; four weeks after coronary artery occlusion to induce heart failure in rats) significantly and selectively abolishes the afferent markers expression (TRPV1 and calcitonin gene-related peptide) in dorsal horn and reduced overactivated CSNA. Resiniferatoxin significantly reverses the prolongation of action potential duration (APD) and APD alternan, reduces the inducibilities of ventricular arrhythmias

Biofargo has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02522611	National Institute of Neurological Disorders and Stroke (NINDS)\|National Institutes of Health Clinical Center (CC)	Intractable Pain\|Palliative Care	October 1, 2023	Phase 1\|Phase 2
NCT05695339	National Institutes of Health Clinical Center (CC)	Morton´s Neuroma	August 28, 2023	Phase 1
NCT04572776	Sorrento Therapeutics, Inc.	Pain, Intractable\|Pain Cancer	December 2020	Phase 3
NCT03542838	Sorrento Therapeutics, Inc.	Osteoarthritis, Knee\|Pain, Knee	July 12, 2018	Phase 1
NCT05067257	Sorrento Therapeutics, Inc.	Pain, Intractable\|Pain Cancer\|Pain	September 2023	Phase 2
NCT04386980	Sorrento Therapeutics, Inc.	Osteoarthritis, Knee\|Osteo Arthritis Knee\|Knee Pain Chronic	April 2021	Phase 3
NCT04885972	Sorrento Therapeutics, Inc.	Osteoarthritis, Knee\|Knee Osteoarthritis\|Knee Pain Chronic	November 15, 2021	Phase 2
NCT04044742	Sorrento Therapeutics, Inc.	Osteoarthritis, Knee\|Knee Pain Chronic	December 2020	Phase 3
NCT00804154	National Institute of Dental and Craniofacial Research (NIDCR)\|National Institute of Neurological Disorders and Stroke (NINDS)\|Sorrento Therapeutics, Inc.\|National Institutes of Health Clinical Center (CC)	Intractable Pain\|Palliative Care	December 2020	Phase 1
NCT03226574	Sorrento Therapeutics, Inc.	Intractable Cancer Pain	September 1, 2017	Phase 1

Specifications

CAS No.	57444-62-9
Formula	C₃₇H₄₀O₉
Molecular Weight	628.71
Appearance	Solid
SMILES	C[C@H]1[C@]23[C@](C=C(C[C@]4([C@@]3([H])C=C(C4=O)C)O)COC(CC5 =CC(OC)=C(C=C5)O)=O)([H])[C@]6([H])[C@](C1)(O[C@](O2)(O6)CC7=CC=CC=C7)C(C)=C
Initial Source	Plants > Euphorbiaceae > Euphorbia resinifera O. Berg
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	-20°C, protect from light In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solution Preparation Table

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration / Solvent / Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.5906 mL	7.9528 mL	15.9056 mL	39.7640 mL
	5 mM	0.3181 mL	1.5906 mL	3.1811 mL	7.9528 mL
	10 mM	0.1591 mL	0.7953 mL	1.5906 mL	3.9764 mL
	15 mM	0.1060 mL	0.5302 mL	1.0604 mL	2.6509 mL
	20 mM	0.0795 mL	0.3976 mL	0.7953 mL	1.9882 mL
	25 mM	0.0636 mL	0.3181 mL	0.6362 mL	1.5906 mL
	30 mM	0.0530 mL	0.2651 mL	0.5302 mL	1.3255 mL
	40 mM	0.0398 mL	0.1988 mL	0.3976 mL	0.9941 mL
	50 mM	0.0318 mL	0.1591 mL	0.3181 mL	0.7953 mL
	60 mM	0.0265 mL	0.1325 mL	0.2651 mL	0.6627 mL

Documents

Data Sheet

SDS

COA

Handling Instruction

Publications

Cell Rep. 2024 Oct 15;43(10):114859.

References

[1]. Brown DC. Resiniferatoxin: The Evolution of the "Molecular Scalpel" for Chronic Pain Relief. Pharmaceuticals (Basel). 2016;9(3):47. Published 2016 Aug 11.

[2]. Wu Y, et al. Resiniferatoxin reduces ventricular arrhythmias in heart failure via selectively blunting cardiac sympathetic afferent projection into spinal cord in rats. Eur J Pharmacol. 2020;867:172836.

For research use only. We do not sell to patients.